Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now shows revision v3.6.5, replacing the previous v3.6.4. This reflects a newer site deployment while the visible content remains the same.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.6.4 was added and Revision: v3.6.3 was removed, indicating a platform/software update for the page. This appears to be a templating or system update with no visible changes to the study content.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a new revision release. This reflects a small administrative update to the page's revision history rather than changes to study content.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page now shows Revision: v3.6.2, updating the revision tag to reflect a software update rather than a change to study details.SummaryDifference0.1%

- Check77 days agoChange DetectedRecruitment status updated to 'No longer looking for participants', indicating the study is not enrolling. New help/navigation sections were added ('How to Read a Study Record', 'Common Questions', 'How to Join a Study'), the Intervention/Treatment heading was added (replacing the old 'Intervention / Treatment' heading), and the revision line was updated to 'Revision: v3.6.0'.SummaryDifference0.4%

- Check84 days agoChange DetectedA new revision label (v3.5.5) replaces the previous v3.5.4 on the study page, indicating an update to the record's metadata.SummaryDifference0.1%

Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.